Therapeutic potential of palmitoylethanolamide in neurodegenerative diseases

Isabela Petrone Arifa and Lucas Daniel Udovin

South Health and Policy, 2024, vol. 3, 140-140

Abstract: The therapeutic potential of palmitoylethanolamide (PEA) in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. He described how PEA, an endogenous compound with anti-inflammatory and neuroprotective properties, acted on neuroinflammation and oxidative stress by activating the PPAR-α receptor. Preclinical and clinical studies were reviewed that showed cognitive and motor improvements after administration, as well as its combination with luteolin to enhance its effect. The need for further research into other diseases such as amyotrophic lateral sclerosis and frontotemporal dementia was also highlighted, emphasising the importance of rigorous methodologies to validate its efficacy.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:southh:2024v3a71

DOI: 10.56294/shp2024140

Access Statistics for this article

More articles in South Health and Policy from AG Editor (Argentina)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().